If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

 

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -0.75 (-3.00%)
Spread: 0.50 (2.083%)
Open: 25.00
High: 25.00
Low: 24.25
Prev. Close: 25.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

13 Oct 2014 08:20

RNS Number : 0908U
Sareum Holdings PLC
13 October 2014
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Sareum Holdings plc.

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

YA Global Master SPV, Ltd

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

October 1 2014

6. Date on which issuer notified:

October 10, 2014

7. Threshold(s) that is/are crossed orreached: vi, vii

Cross 3% Threshold

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect x

Direct

Indirect

65,665,125

65,665,125

55,962,500

55,962,500

2.9

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

55,962,500

2.9%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Steven Goldstein

15. Contact telephone number:

201-985-8300

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in share

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

YA Global Master SPV, Ltd

Contact address

(registered office for legal entities)

 

1012 Springfield Ave., Mountainside, NJ 07092

Phone number & email

 

201-985-8300

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Steven S. Goldstein

Contact address

 

1012 Springfield Ave., Mountainside, NJ 07092

Phone number & email

 

201-985-8300 & sgoldstein@yorkvilleadvisors.com

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLMJBRTMBBBMAI
Date   Source Headline
7th May 20242:10 pmRNSExercise of Warrants
23rd Apr 20247:00 amRNSFinal Issue of RiverFort Subscription Shares
19th Apr 202411:35 amRNSIssue of RiverFort Subscription Shares
15th Apr 20243:28 pmRNSIssue of RiverFort Subscription Shares
9th Apr 20244:00 pmRNSIssue of RiverFort Subscription Shares
4th Apr 20242:38 pmRNSCompletion of Equity Fundraise
2nd Apr 20244:51 pmRNSResult of WRAP Retail Offer
2nd Apr 20247:00 amRNSIncrease in size of WRAP Retail Offer
28th Mar 20247:02 amRNSWRAP Retail Offer
28th Mar 20247:01 amRNSEquity Fundraise
28th Mar 20247:00 amRNSSareum Half-Year Report
15th Mar 20247:00 amRNSNew Patent Allowance
12th Mar 20241:30 pmRNSNotice of Interim Results and Trading Update
15th Feb 20247:00 amRNSUpdate on SDC-1801 Clinical Trial Progress
2nd Jan 20247:00 amRNSDevelopment and commercialisation licence SRA737
14th Dec 20233:35 pmRNSResults of AGM
14th Dec 20237:00 amRNSAnnual General Meeting Statement
23rd Nov 20237:00 amRNSDrawdown of Equity Prepayment Facility
21st Nov 20237:00 amRNSNotice of AGM, Annual Report and Accounts
9th Nov 20237:00 amRNSInitiation of food effects study for SDC-1801
8th Nov 20233:03 pmRNSDirector Dealings
3rd Nov 20237:05 amRNSSareum enhances SDC-1801 patent protection
2nd Nov 20232:48 pmRNSExercise of Share Options and Director Dealings
9th Oct 20237:00 amRNSFinal Results for the Year Ended 30 June 2023
3rd Oct 20237:00 amRNSNotice of Results and Investor Presentation
6th Sep 20237:00 amRNSDirector's Dealing
5th Sep 20237:00 amRNSDirector Dealing
4th Sep 20237:00 amRNSDosing of first subjects in MAD Phase 1a trial
16th Aug 20237:00 amRNSUpdate on financial and operational progress
3rd Aug 20237:00 amRNSEquity Prepayment Facility of up to £5 million
26th Jun 20237:00 amRNSSareum Announces Two New Granted Patents
6th Jun 20237:00 amRNSDosing commences in Phase 1a trial of SDC-801
18th May 20237:00 amRNSPhase 1a clinical trial for SDC-1801
5th May 20239:20 amRNSApproval to initiate Phase 1 clinical trial
22nd Mar 20237:00 amRNSHalf-Year Report
15th Mar 20237:01 amRNSUpdate on SDC-1801
15th Mar 20237:00 amRNSNotice of Half-Year Results
6th Mar 20237:00 amRNSUpdate on SRA737
29th Dec 20223:14 pmRNSDirector/PDMR Shareholding
16th Dec 20223:29 pmRNSResults of AGM
16th Dec 20227:00 amRNSAGM Statement
24th Nov 20227:00 amRNSNotice of AGM, Annual Report and Accounts
21st Nov 20227:00 amRNSSareum notes publication of SRA737 clinical data
9th Nov 20224:41 pmRNSSecond Price Monitoring Extn
9th Nov 20224:35 pmRNSPrice Monitoring Extension
9th Nov 20222:05 pmRNSSecond Price Monitoring Extn
9th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 202211:05 amRNSSecond Price Monitoring Extn
9th Nov 202211:00 amRNSPrice Monitoring Extension
9th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.